Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. (Record no. 30925080)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02333 a2200649 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518101428.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202007s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1474-5488 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/S1470-2045(20)30061-9 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ledermann, Jonathan A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20200709 |
| 245 00 - TITLE STATEMENT | |
| Title | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | The Lancet. Oncology |
| Date of publication, distribution, etc. | 05 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 710-722 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carcinoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease Progression |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Double-Blind Method |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Indoles |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm Recurrence, Local |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ovarian Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Platinum |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Poly(ADP-ribose) Polymerase Inhibitors |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Progression-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oza, Amit M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lorusso, Domenica |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aghajanian, Carol |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oaknin, Ana |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dean, Andrew |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Colombo, Nicoletta |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Weberpals, Johanne I |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Clamp, Andrew R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Scambia, Giovanni |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leary, Alexandra |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Holloway, Robert W |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gancedo, Margarita Amenedo |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fong, Peter C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Goh, Jeffrey C |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | O'Malley, David M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Armstrong, Deborah K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Banerjee, Susana |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | García-Donas, Jesus |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Swisher, Elizabeth M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cameron, Terri |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maloney, Lara |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Goble, Sandra |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Coleman, Robert L |
| 773 0# - HOST ITEM ENTRY | |
| Title | The Lancet. Oncology |
| Related parts | vol. 21 |
| -- | no. 5 |
| -- | p. 710-722 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/S1470-2045(20)30061-9">https://doi.org/10.1016/S1470-2045(20)30061-9</a> |
| Public note | Available from publisher's website |
No items available.